Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs. The deal would help Roche grow in a field related to the booming weight-loss market, where the company has recently made … Read more